Elafibranor moves to Phase 3 Study called ELATIVE

Elafibranor moves to Phase 3 Study called ELATIVE

Elafibranor moves to Phase 3 Study called ELATIVE

The Phase 3 study will consist of Elafibranor 80mg for double blind period (52 to 104 weeks). After completion of the double blind period, participants will be offered the opportunity to enter an open label long term extension study for up to 5 years. Participants will continue the elafibranor dose received during the double blind period. Read more about the study.